January 10, 2022
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
Media
January 07, 2022
Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma
January 05, 2022
Hemab Therapeutics Appoints John Maraganore as Chair of Board of Directors and Welcomes New Additions to Board and Leadership Team
January 05, 2022
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
January 05, 2022
Oncopeptides announces year-end cash 2021
January 03, 2022
Xeris Biopharma Enters Into Agreement for $30 Million Private Placement
December 30, 2021
Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
December 23, 2021
Oncorena Secures Financing of the Company’s Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer
December 20, 2021
Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma
December 16, 2021
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma
